Harvest Fund Management Co. Ltd Buys 8,298 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Harvest Fund Management Co. Ltd lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 410.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 10,319 shares of the biopharmaceutical company’s stock after purchasing an additional 8,298 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Alnylam Pharmaceuticals were worth $4,103,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the stock. Prudential PLC boosted its holdings in shares of Alnylam Pharmaceuticals by 1.7% in the fourth quarter. Prudential PLC now owns 7,829 shares of the biopharmaceutical company’s stock worth $3,113,000 after acquiring an additional 133 shares during the period. Westfield Capital Management Co. LP boosted its holdings in shares of Alnylam Pharmaceuticals by 6.3% in the fourth quarter. Westfield Capital Management Co. LP now owns 93,444 shares of the biopharmaceutical company’s stock worth $37,158,000 after acquiring an additional 5,536 shares during the period. Vise Technologies Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 47.9% in the fourth quarter. Vise Technologies Inc. now owns 1,515 shares of the biopharmaceutical company’s stock worth $602,000 after acquiring an additional 491 shares during the period. Globeflex Capital L P bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $133,000. Finally, Daiwa Securities Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 67.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 25,999 shares of the biopharmaceutical company’s stock worth $10,339,000 after acquiring an additional 10,503 shares during the period. 92.97% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider Melissa Mclaughlin sold 2,286 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the sale, the insider owned 9,443 shares in the company, valued at approximately $3,120,156.06. This trade represents a 19.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director owned 1,582 shares in the company, valued at $473,302.76. The trade was a 70.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,740 shares of company stock worth $2,420,214 in the last quarter. 0.86% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Trading Up 3.8%

Shares of ALNY stock opened at $303.64 on Friday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. Alnylam Pharmaceuticals, Inc. has a 52-week low of $283.10 and a 52-week high of $495.55. The company has a market capitalization of $40.54 billion, a PE ratio of 82.96 and a beta of 0.29. The business’s fifty day moving average is $308.18 and its 200 day moving average is $349.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter last year, the business posted ($0.44) earnings per share. The firm’s revenue was up 96.4% compared to the same quarter last year. On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Citigroup assumed coverage on Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price target for the company. Freedom Capital raised Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th. Canaccord Genuity Group raised their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $463.13.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.